All News

2057 articles, sorted by publication time.

Gene and Cell Therapy · us

Directly correcting the sickle cell mutation, nula-cel receives FDA Regenerative Medicine Advanced Therapy designation

Three patients no longer need transfusions and have experienced no vaso-occlusive events after treatment, giving nula-cel access to closer development discussions with the FDA. But the evidence underlying this regulatory milestone remains very early, and more complete data are needed to determine how long the benefits last and what safety trade-offs treatment entails.

Clinical Trials and New Drugs · us

enGene updates trial results for bladder cancer gene therapy detalimogene, plans to begin FDA submission by year-end

Among high-risk patients unresponsive to BCG treatment, 56% achieved a complete response at some point, but the complete response rate at 12 months was 24%. As follow-up data mature, this bladder-preserving therapy is moving toward a marketing application, with the durability of efficacy remaining a key focus for review.

Biotech Industry · global

Pfizer’s Monthly Weight-Loss Drug Secures Up to $1.5 Billion in R&D Funding, With Blackstone’s Returns Tied to Approval and Sales

Blackstone will share berobenatide’s development costs through 2028, while Pfizer retains rights to the drug and decision-making authority. The funding supports a program encompassing 10 ongoing or planned Phase 3 trials, but the efficacy and safety of once-monthly injections still require clinical evidence.